Novo CEO Says Planned Semaglutide GLP-1 Pill Reflects Innovative Strategy
This article was originally published in The Pink Sheet Daily
Novo Nordisk says plans to start Phase II studies of an oral version of its once-weekly injected human GLP-1 analogue semaglutide reflect the Danish company’s commitment to innovate by addressing a wider segment of the growing diabetes and pre-diabetes market.
You may also be interested in...
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.